myelodysplastic syndromes (MDS) | Page 4 | Aplastic Anemia & MDS International Foundation Return to top.

myelodysplastic syndromes (MDS)

2022 Seattle, WA, Patient and Family Virtual Conference

Please find the presentation materials below.

Event Date: 
Sat, 06/18/2022 - 9:00am (EDT)
Conference Event Type: 

Patients With MPNs Must Be Honest About Their Symptoms, Says Expert

It is incredibly important that patients with MPNs inform their health care team of any symptoms they are experiencing, according to an expert from The Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center.

Because patients with essential thrombocythemia (ET) or polycythemia vera (PV) — rare types of blood cancers known as myeloproliferative neoplasms (MPNs) — experience a range of symptoms that can significantly impact their quality of life, it’s important that patients communicate what they’re experiencing with their health care team.

VEXAS Syndrome

In this webinar, Dr. David Beck, MD, PhD and Anna Cantor, MA, MS, CGC, discuss VEXAS syndrome which is a newly discovered auto-inflammatory condition affecting older adults.  VEXAS syndrome often overlaps with

Catherine J. Lee, MD

Lee, Catherine
Associate Professor of Medicine in the Division of Hematology/BMT
Huntsman Cancer Center, University of Utah

Dr. Catherine Lee's clinical expertise is in Blood and Marrow Transplantation (BMT) & Cellular Therapy. She specializes in autologous and allogeneic hematopoietic cell transplants for the treatment of malignant and benign hematologic diseases in adult patients. She also directs the clinical cellular therapy program and provides both standard-of-care cellular therapy treatments and those being tested in clinical trials.

Aplastic Anemia, MDS, and PNH Virtual Support Group - 2022 July

Event Date: 
Sat, 07/23/2022 - 10:30am (EDT)

AAMDSIF is pleased to announce that we will host a support group for patients diagnosed with

Share with